In the news
Rethinking brain treatment: Neumic's vision featured on BusinessDesk
Professor John Reynolds, CEO and co-founder of Neumic Therapeutics, discusses the company's pioneering approach to brain therapy in a national television business interview, exploring how focused ultrasound could transform the treatment of neurological conditions.
- Published OCT 28, 2026
Building on more than two decades of neuroscience research at the University of Otago, Neumic is developing a technology platform combining wearable focused ultrasound, precision targeting software and specially designed drug carriers to deliver treatment to specific regions of the brain, at the time it is needed. The ambition is to move beyond treatments that act broadly throughout the brain, towards therapies that respond to the precise needs of individual brain circuits.
Watch the interview to discover the science behind Neumic, the opportunity to rethink treatment for conditions such as Parkinson's disease, and the company's journey from pioneering research towards clinical application.
